Torthaí cuardaigh - Lijin Zhao

  • 1 - 3 toradh as 3 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Significant Response to Palbociclib Plus Lenvatinib as Second-line Treatment for CDKN2A/2B Deletion Intrahepatic Cholangiocarcinoma: A Case Report

    Significant Response to Palbociclib Plus Lenvatinib as Second-line Treatment for CDKN2A/2B Deletion Intrahepatic Cholangiocarcinoma: A Case Report de réir Kai Liu, Ziyue Huang, Lijin Zhao, Haitao Zhao

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy

    TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy de réir Jin-feng Shen, Zaiyou Dai, Yunsheng Li, Huiping Zhu, Lijin Zhao

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects

    Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects de réir Xuan-Yu Gu, Jinlong Huo, Zhiyong Yu, Ji-Chang Jiang, Yaxuan Xu, Lijin Zhao

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: